Comment on

• Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.

  Ochoge M, Futa AC, Umesi A, Affleck L, Kotei L, Daffeh B, Saidy-Jah E, Njie A, Oyadiran O, Edem B, Jallow M, Jallow E, Donkor SA, Tritama E, Abid T, Jones KAV, Mainou BA, Konz JO, Fix A, Gast C, Clarke E. Ochoge M, et al. Lancet. 2024 Mar 23;403(10432):1164-1175. doi: 10.1016/S0140-6736(23)02844-1. Epub 2024 Feb 22. Lancet. 2024. PMID: 38402887 Free PMC article. Clinical Trial.